AI research for doctors and clinicians carries patient safety implications that make the verification requirements more stringent than in almost any other field. An AI hallucination in a clinical research context isn't a credibility problem — it's a potential patient safety event. The protocol for AI-assisted clinical research reflects this reality.
This guide covers where AI genuinely accelerates clinical research, where it creates risk, what the two-track protocol looks like, and what the compliance and institutional considerations require.
What AI Does Well for Clinical Research
Understanding where AI is genuinely useful is the first step toward using it well.
Strong AI use cases in clinical research:
Literature mapping: AI can rapidly identify the major categories of evidence relevant to a clinical question, name the landmark trials in an area, and characterize the state of the evidence (well-established vs. actively contested vs. emerging). This orientation function saves 30-45 minutes of initial literature searching — with the important caveat that the specific citations AI provides require verification.
Systematic review acceleration: for literature reviews that would require 200+ PubMed searches, AI tools trained on medical literature can identify relevant papers, screen abstracts for inclusion/exclusion criteria, and summarize themes across included studies. Human verification of the search results and inclusion decisions is still required, but the acceleration is real.
Clinical documentation drafting: AI is strong at drafting clinical documentation (progress notes, discharge summaries, operative notes, consult notes) from structured inputs — the clinician provides the clinical facts and key decision rationale; AI generates a draft in the appropriate format. The clinician reviews, edits, and signs. The AI provides the structure and language; the clinical content and accuracy judgment are the clinician's.
Patient education material generation: AI can translate evidence-based recommendations into patient-accessible language at specified reading levels, creating first drafts of patient education materials that the clinician then reviews for accuracy and appropriateness.
Differential diagnosis generation: AI can generate a differential diagnosis list from a described presentation, often broader than a single clinician's initial consideration. This functions as a checklist rather than a diagnostic conclusion — the AI generates candidates; the clinician evaluates them against the full clinical picture.
Risky AI use cases in clinical research (verification required):
Specific drug dosing: AI can be incorrect about specific dosing, particularly for renally-adjusted doses, pediatric doses, or uncommon medications. Always verify drug dosing in a clinical pharmacology reference (Micromedex, Lexicomp) rather than relying on AI output.
Current guideline status: AI training data has a cutoff. A guideline that was current at training time may have been updated. Always verify guideline currency on the issuing society's website.
Drug-drug interactions: AI can miss interactions or generate interactions that aren't clinically significant. Clinical pharmacology references (Micromedex, Lexicomp, Epocrates) are the authoritative source for drug interaction checking.
Rare disease management: AI training data is proportional to publication volume. Rare diseases are underrepresented, and AI recommendations for rare disease management may be unreliable. Primary literature and subspecialty consultation are more reliable sources for rare disease management.
Specific study citations: AI hallucinates citations, including in medical contexts. Never cite an AI-provided citation without verifying it in PubMed.
The Two-Track Protocol
Track 1 — AI for Orientation and Acceleration:
For literature mapping, synthesis drafting, and documentation generation. AI is used where it's genuinely strong, with the understanding that its outputs are starting points, not conclusions.
Track 1 prompt discipline for clinical questions:
Frame prompts without patient-identifying information:
- "What are the major classes of evidence for first-line treatment of HFpEF in patients over 75?" (safe)
- "My 78-year-old patient with HFpEF [identifies patient]" (avoid in AI prompts)
Ask for conceptual orientation before specific citations:
- "What are the landmark trials in this area and what did they establish?" then verify specific trials in PubMed
- Rather than "What does the EMPEROR-Preserved trial show?" which requests a specific citation the AI may misrepresent
Track 2 — Verified Clinical Sources for All Substantive Claims:
All clinical claims that will inform patient care decisions are verified through authoritative clinical sources:
| Clinical question type | Authoritative source |
|---|
| Point-of-care evidence synthesis | UpToDate, DynaMed |
| Primary literature | PubMed, Cochrane Library |
| Drug dosing | Micromedex, Lexicomp |
| Drug-drug interactions | Micromedex, Lexicomp, Epocrates |
| Current guidelines | Issuing society website or guidelines database |
| Drug approvals and safety alerts | FDA.gov |
Track 2 verification is non-negotiable for patient care decisions. AI provides orientation; authoritative sources provide verification.
| Tool | Clinical Research Use | Verification Required |
|---|
| Clinical AI tools (Doximity, Amboss AI) | Point-of-care question answering, literature orientation | All dosing and guideline claims; specific citations |
| GPT-4 / Claude (general AI) | Literature mapping, documentation drafting, patient education | All clinical claims; all specific citations; dosing always |
| PubMed AI search tools (NLM AI assistant) | Literature search assistance | Search results still require human abstract screening |
| Clinical NLP for documentation (Nuance DAX, Suki) | Clinical documentation drafting from voice input | Clinician review before signature; all clinical facts |
| IBM Watson for Oncology / similar | Complex case analysis for specific specialties | Clinician judgment on recommendation application; institutional validation required |
Special considerations for integrated clinical AI tools:
Several health systems and EMR vendors are integrating AI tools directly into clinical workflows. These tools may have access to the patient record and provide AI-generated suggestions within the clinical workflow. Institutional validation of these tools, ongoing monitoring of AI recommendation accuracy, and clear policies on clinician override of AI suggestions are all required components of responsible implementation.
Patient Privacy in AI Research Contexts
The core principle: AI tools used for clinical research should not receive patient-identifiable information unless the tool is covered by a BAA (Business Associate Agreement) and meets HIPAA compliance requirements.
Most general AI tools (ChatGPT, Claude, etc.) are not HIPAA-compliant business associates and cannot legally receive PHI. Using these tools with patient data creates both a HIPAA violation and a patient trust violation.
Safe practice:
- Use AI for clinical research on de-identified or hypothetical cases
- For EMR-integrated AI tools: confirm whether the tool has a valid BAA with the institution before use
- Anonymize or hypotheticalize clinical questions before AI prompting: "A patient with [condition] and [comorbidities]..." rather than any patient-identifying framing
- Know your institution's policy on AI tool use with clinical information before using any AI tool in the clinical context
Institutional AI policies:
Many health systems now have formal policies on AI use in clinical practice. These policies typically address: which AI tools are approved for clinical use, what data can be submitted to which tools, how AI suggestions should be documented in the clinical record, and what override authority clinicians have when they disagree with AI recommendations. Know your institution's policy.
A Worked Example: AI in an Academic Case Report
The case: an unusual presentation of a known condition that warrants case report publication.
AI for literature mapping (Track 1):
Prompt (de-identified): "What is the existing literature on [condition] presenting with [unusual feature]? What are the major case series, and is there any systematic review of this presentation variant?"
AI response: identifies 3-4 relevant papers by approximate description, characterizes the state of the literature ("limited to case reports; no systematic review"), and identifies the clinical question the case report would address.
Track 2 verification:
PubMed search using the MeSH terms and clinical terms AI identified. The 3-4 papers AI mentioned are located — 2 are found and accurately described; 1 has the correct citation but a different conclusion than AI stated; 1 doesn't appear to exist in PubMed (hallucinated citation). Additional PubMed search identifies 2 relevant papers AI didn't mention.
AI for manuscript drafting (Track 1):
The background section is drafted using the 5 verified papers found in PubMed. AI generates a first draft of the background section from the structured synthesis provided. Clinician reviews, revises for accuracy and emphasis, verifies that each citation claim matches the source.
Result: the literature review that would have taken 2-3 hours of initial PubMed searching was oriented in 20 minutes with AI assistance and completed in 45 minutes of targeted PubMed verification. The draft background section that would have taken 1 hour to write took 30 minutes (AI draft) + 15 minutes of review and revision.
Key Takeaways
-
AI research for doctors and clinicians requires a two-track protocol because patient safety is at stake. Track 1 (AI for orientation, synthesis, documentation drafting): AI used where it's genuinely strong; outputs are starting points. Track 2 (authoritative clinical sources for all substantive claims): UpToDate/DynaMed for synthesis, PubMed for primary literature, Micromedex/Lexicomp for dosing and interactions, society websites for guidelines.
-
Never verify drug dosing, drug interactions, or specific citations from AI alone. These are the highest-risk hallucination areas in clinical contexts. Drug dosing always comes from clinical pharmacology references (Micromedex, Lexicomp); drug interactions always from interaction checkers; specific citations always from PubMed.
-
Patient-identifiable information should not be submitted to non-HIPAA-compliant AI tools. Most general AI tools are not HIPAA-compliant business associates. Clinical research prompts should be de-identified or hypotheticalized before submission to any AI tool that doesn't have a valid BAA.
-
AI for clinical documentation drafting is a strong use case. When the clinician provides the clinical facts and decision rationale, AI generates well-structured documentation from those inputs. The clinician reviews, edits for accuracy, and signs. AI provides structure and language; clinical content and judgment remain human.
-
Know your institution's AI policy before using AI in clinical contexts. Approved tools, data submission policies, documentation requirements, and override authority are increasingly defined at the institutional level. Operating outside the institutional policy creates both compliance and liability risk.
Conclusion
AI-assisted research for doctors and clinicians produces real efficiency gains in literature orientation, synthesis drafting, documentation generation, and patient communication — while requiring Track 2 verification through authoritative clinical sources for all substantive claims that inform patient care, strict de-identification for privacy compliance, and human clinical judgment for all patient care decisions. The two-track protocol captures the acceleration benefits of AI without the patient safety risk of treating AI outputs as clinical authority. In clinical research as in clinical practice: AI is a tool that supports clinical reasoning; it doesn't replace it.
See also: The Ultimate Guide to Web Clipping.